ELTP News .15 Elite Pharmaceuticals Announces I
Post# of 144406
ELTP News .15
Elite Pharmaceuticals Announces Issuance of U.S. Patent for Abuse Resistant Oral Dosage Formulation
2012-05-22 09:32 ET - News Release
NORTHVALE, N.J., May 22, 2012 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced the issuance of U.S Patent No. 8,182,836 entitled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof" by the United States Patent and Trademark Office (USPTO). The issuance of this patent will further protect Elite's proprietary formulation for abuse resistant products utilizing the pharmacological approach. The Company has additional patents pending for its technology.
"The issuance of this patent is an important milestone for the company. It validates our pharmacological approach to the development of abuse-resistant drug products and provides additional value for these products," said Jerry Treppel, Elite's Chairman and CEO.
About Elite Pharmaceuticals, Inc.
(0)
(0)